What You Should Know:
2023 started off with the hallmarks of a rebound year. While Q4 2022 signaled the tail end of the digital health funding cycle, January and February funding numbers began to suggest that sector investment was slowly but surely inching back upwards. Inflation was easing ever so slightly. Investors were rediscovering their confidence and launching new projects, signaling optimism in the sector, according to a new Rock Health report. However, recent news—the collapse of
Read More
PEAR Therapeutics
Analysis: Seeking Balance in the Hyperactive Mental Health Tech Market
The prevalence of mental and behavioral health conditions has been on the rise in recent decades, further aggravated by the pandemic in the last two years. Social isolation, grief from the loss of loved ones, fear of contracting the virus, and financial worries were all major stress factors that increasingly affected the mental wellbeing of the population, and the resulting statistics are startling: the average share of adults with symptoms of anxiety or depressive disorders jumped from 1
Read More
Pear Therapeutics Acquires 2 Depression Assets to Optimize Depression Product Candidate
What You Should Know:
- Pear Therapeutics, Inc. (Nasdaq: PEAR), announced it has acquired two new digital therapeutic assets that it intends to integrate into a potential prescription digital therapeutic (PDT) to treat patients across a continuum of depression subtypes and severities.
- Additionally, Pear announced yesterday the expansion of its existing initiative with Crossroads. Through this expansion, Pear’s PDTs, reSET® and reSET-O®, have the potential to reach thousands of additional
Read More
Pear Therapeutics Goes Public Via $1.6B SPAC Deal – Digital Health IPO
What You Should Know:
- Pear Therapeutics, the leader in developing and commercializing prescription digital therapeutics to treat serious disease, and Thimble Point Acquisition Corp (Nasdaq: THMA), a special purpose acquisition company (SPAC) whose management team is associated with the Pritzker Vlock Family Office, today announced that they have entered into a definitive business combination agreement.
- Pursuant to the Business Combination Agreement, upon closing of the
Read More
Pear Therapeutics Raises $80M to Advance Prescription Digital Therapeutics
What You Should Know:
- Pear Therapeutics today announced that it has
successfully closed an $80 million Series D financing led by SoftBank Vision
Fund 2.
- Pear is the
leader in prescription digital therapeutics and the first company to receive
FDA authorization for a prescription digital therapeutic (PDT) to treat
disease.
- Pear currently has three FDA authorized therapies, reSET, reSET-O and Somryst, for substance use disorder, opioid use disorder, and chronic insomnia,
Read More
PreferredOne Becomes First Health Plan to Cover Prescription Digital Therapeutics
What You Should Know:
- PreferredOne teams with Pear to provide its members
with covered access to two prescription digital therapeutics (PDTs) for the
treatment of substance use disorder (SUD) and opioid use disorder (OUD)
- PDTs are a new therapeutic class that uses software to
directly treat disease. Like traditional medicines, PDTs are tested in
randomized controlled trials demonstrating safety and effectiveness, evaluated
and authorized by regulators like FDA, and used under the
Read More
CB Insights Unveils ‘Digital Health 150’ List of Startups Transforming Healthcare
- CB Insights unveils first-ever annual ‘Digital Health 150’ list of digital health startups working to transform the healthcare industry.
- The Digital Health 150 companies span a wide spectrum of categories that involve all three key stakeholder groups for the healthcare industry — providers, payers, and patients.
- A total of 17 companies on the list are unicorns (private companies valued at $1B+). Of these, 12 companies are US-based, 3 are based in China, 1 is based in France, and 1
Read More
Magellan Health Launches First FDA-Approved Prescription Digital Therapeutic
Magellan Health has announced the launch of reSET therapy, a pilot initiative using the first-ever FDA cleared prescription digital therapeutic from PEAR Therapeutics to improve outcomes for individuals struggling with Substance Use Disorders (SUD) and other related conditions.With the current challenges in our nation related to substance use, the evidence-based, non-drug treatment option presented with this approach is an opportunity to offer a practical solution to meet these complex needs and
Read More
